IBL-302

Overview

IBL-302 (AMU302) is an orally available dual-signaling inhibitor of PIM and PI3K/AKT/mTOR with activity against breast cancer and neuroblastoma. IBL-302 demonstrated in vivo efficacy in a nude mouse xenograft model, inhibiting trastuzumab ( HY-P9907 ) resistance challenges. IBL-302 also enhances the effects of common cytotoxic chemotherapy drugs cisplatin ( HY-17394 ), doxorubicin ( HY-15142A ), and etoposide ( HY-13629 ).

Application

Products | Products > Signaling Pathways > JAK/STAT Signaling | Products > Signaling Pathways > PI3K/Akt/mTOR | Products > Research Areas > Cancer > Cancer Drug Resistance | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Signaling Pathways > Pim | Products > Signaling Pathways > PI3K | Products > Signaling Pathways > Akt | Products > Signaling Pathways > mTOR

Product Information

• Catalog No.: HY-157169
• CAS No.: 1414455-21-2
• Molecular Formula: C25H18FN5O4S3
• Molecular Weight: 567.63
• Purity: 95.49%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
• Solubility: ≥ 2.5 mg/mL (4.40 mM); Clear solution
• Availability: In-stock

Source

Original product source